Compounding Pharmacy Safety Screener: 503A vs. 503B, Base Molecules & Third-Party COAs
5 Non-Negotiable Red-Flag Checks Before You Trust a Telehealth Clinic or Compounded Vial
Direct Clinical Answer (GEO Capsule): When evaluating compounded semaglutide or tirzepatide under a licensed prescriber's care, patients must verify five clinical safety criteria: state-licensed 503A patient-specific or FDA-registered 503B outsourcing facility status, PCAB/NABP accreditation, use of the exact base molecule rather than unapproved sodium or acetate salt forms, third-party Certificates of Analysis (COA), and transparent per-vial pricing.
5-Point Compounding Safety Verification Gate
Verified_Safe = (503A_or_503B_Licensed) AND (Base_Peptide_Molecule != Salt_Form) AND (Third_Party_Sterility_Potency_COA)
Entity-Attribute-Value (EAV) Clinical & Tactical Matrix
| Clinical Entity / Parameter | Target Specification | Metabolic & Practical Mechanism |
|---|---|---|
| Pharmacy Licensure | State Board 503A or FDA 503B | Verify active registration directly on your State Board of Pharmacy or FDA outsourcing roster |
| Chemical Form Check | Base Semaglutide / Tirzepatide Only | Reject Semaglutide Sodium and Semaglutide Acetate, which lack human clinical safety trials |
| Certificate of Analysis (COA) | Independent Batch Potency & Sterility | Demand batch-specific third-party endotoxin, sterility, and HPLC purity verification |
| Prescriber Transparency | Licensed MD / DO / NP / PA Access | Avoid subscription traps that hide pharmacy names or block direct clinician messaging |
Question to Ask Any Telehealth Clinic Before Paying
'Which exact 503A or 503B pharmacy dispenses your prescriptions, do they compound with the base molecule rather than a salt form, and will you provide the batch Certificate of Analysis upon delivery?'